BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo

What happened: BioNTech ($BNTX) and Gilead Sciences announced a clinical trial collaboration to test pumitamig, BioNTech's bispecific immunomodulator, combined with a Gilead antibody-drug conjugate in a global Phase 3 study in first-line metastatic triple-negative breast cancer. Key numbers: Market value about $22.0 billion. Fair value cited at $117. Why it matters: The content frames the deal as central to BioNTech's oncology pivot as COVID-19 revenue declines, while raising execution pressure because more depends on pumitamig working across multiple tumor types. Market: -0.7% today ($86.92), -10.1% YTD, 1.0x vol — as of 23:46 UTC

BioNTech ($BNTX) and Gilead Sciences announced a clinical trial collaboration to test pumitamig, BioNTech's bispecific immunomodulator, combined with a Gilead antibody-drug conjugate in a global Phase 3 study in first-line metastatic triple-negative breast cancer.

The content frames the deal as central to BioNTech's oncology pivot as COVID-19 revenue declines, while raising execution pressure because more depends on pumitamig working across multiple tumor types. Market: -0.7% today ($86.92), -10.1% YTD, 1.0x vol — as of 23:46 UTC